Nyxoah SA (NYXH)
NASDAQ: NYXH · Real-Time Price · USD
0.8715
-0.0164 (-1.85%)
At close: Oct 30, 2026, 4:00 PM EST
0.9161
+0.0446 (5.12%)
Pre-market: Nov 2, 2026, 4:02 AM EST
Company Description
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea.
Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea.
The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah SA
| Country | Belgium |
| Founded | 2009 |
| IPO Date | Jul 2, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 154 |
| CEO | Liam Kelly |
Contact Details
Address: Rue Edouard Belin 12 Mont-Saint-Guibert, 1435 Belgium | |
| Phone | 32 1 045 90 75 |
| Website | nyxoah.com |
Stock Details
| Ticker Symbol | NYXH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $30.00 |
| CIK Code | 1857190 |
| ISIN Number | BE0974358906 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Liam J. Kelly | Chief Executive Officer |
| Robert Taub MBA | Co-Founder and Chairman |
| Bruno Onkelinx | Chief Technical Officer |
| Loic Moreau | President of International and Interim Chief Financial Officer |
| Jeyakumar Subbaroyan | Chief Science Officer |
| Remi Renard | Head of Investor Relations and Corporate Communication |
| An Moonen | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 20, 2026 | 6-K | Report of foreign issuer |
| Sep 29, 2026 | 6-K | Report of foreign issuer |
| Sep 22, 2026 | 6-K | Report of foreign issuer |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 5, 2026 | 6-K | Report of foreign issuer |
| Jul 9, 2026 | 6-K | Report of foreign issuer |
| Jul 1, 2026 | SCHEDULE 13G/A | Filing |
| Jun 23, 2026 | 6-K | Report of foreign issuer |
| Jun 22, 2026 | SCHEDULE 13G | Filing |
| Jun 11, 2026 | 6-K | Report of foreign issuer |